N-叔丁氧羰基-L-4-苯甲酰基苯丙氨酸 | 104504-43-0

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-叔丁氧羰基-L-4-苯甲酰基苯丙氨酸
• 中文别名: Boc-4-苯甲酰基-L-苯丙氨酸；Boc-L-4-苯甲酰基苯丙氨酸；BOC-L-4-苯甲酰基苯丙氨酸
• 英文名称: N-tert-butoxycarbonyl-(S)-3-(4-benzoylphenyl)alanine
• 英文别名: N-boc-4-benzoyl-L-phenylalanine；Boc-LBpa-OH；4-benzoyl-N[(1,1,-dimethylethoxy)carbonyl]-L-phenylalanine；BOC-(4'-benzoyl)-L-phenylalanine；L-Boc-Bpa-OH；4-benzoyl-N-(tert-butoxycarbonyl)-L-phenylalanine；N-(t-butoxycarbonyl)-4-benzoyl-L-phenylalanine；butyloxycarbonyl-4-benzoyl-L-phenylalanine；N-Boc-p-benzoyl-L-phenylalanine；Boc-p-benzoylphenylalanine；N-t-Butyloxycarbonyl-p-Benzoyl-L-Phenylalanine；4-benzoyl-N-Boc-L-phenylalanine；BOC-p-benzoyl-L-phenylalanine；N1-Boc-Bpa-OH；Boc-Bpa；boc-p-bz-Phe-OH；Boc-4-benzoyl-L-phenylalanine；(2S)-3-(4-benzoylphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 104504-43-0
• 化学式: C₂₁H₂₃NO₅
• 分子量: 369.417
• InChiKey: HIQJNYPOWPXYIC-KRWDZBQOSA-N

物化性质

• 沸点：
  561.4±50.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  92.7
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-bpa-oh
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-bpa-oh
CAS number: 104504-43-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C21H23NO5
Molecular weight: 369.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-叔丁氧羰基-L-4-苯甲酰基苯丙氨酸 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 methyl (S)-3-(4-benzoylphenyl)-2-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)propanoate
  参考文献：
  名称：

  Native FKBP12 Engineering by Ligand-Directed Tosyl Chemistry: Labeling Properties and Application to Photo-Cross-Linking of Protein Complexes in Vitro and in Living Cells

  摘要：

  The ability to modify target "native" (endogenous) proteins selectively in living cells with synthetic molecules should provide powerful tools for chemical biology. To this end, we recently developed a novel protein labeling technique termed ligand-directed tosyl (LDT) chemistry. This method uses labeling reagents in which a protein ligand and a synthetic probe are connected by a tosylate ester group. We previously demonstrated its applicability to the selective chemical labeling of several native proteins in living cells and mice. However, many fundamental features of this chemistry remain to be studied. In this work, we investigated the relationship between the LDT reagent structure and labeling properties by using native FK506-binding protein 12 (FKBP12) as a target protein. In vitro experiments revealed that the length and rigidity of the spacer structure linking the protein ligand and the tosylate group have significant effects on the overall labeling yield and labeling site. In addition to histidine, which we reported previously, tyrosine and glutamate residues were identified as amino acids that are modified by LDT-mediated labeling. Through the screening of various spacer structures, piperazine was found to be optimal for FKBP12 labeling in terms of labeling efficiency and site specificity. Using a piperazine-based LDT reagent containing a photoreactive probe, we successfully demonstrated the labeling and UV-induced covalent cross-linking of FKBP12 and its interacting proteins in vitro and in living cells. This study not only furthers our understanding of the basic reaction properties of LDT chemistry but also extends the applicability of this method to the investigation of biological processes in mammalian cells.

  DOI：

  10.1021/ja209641t
• 作为产物：
  描述：

  三丁基苯基锡 在 sodium hydroxide 、 三苯基膦 、 palladium dichloride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 N-叔丁氧羰基-L-4-苯甲酰基苯丙氨酸
  参考文献：
  名称：

  A concise synthesis of photoactivatable 4-Aroyl-l-phenylalanines

  摘要：

  An efficient preparation of the title compounds from 4-iodo-L-phenylalanines using a carbonylative Stille cross-coupling reaction as the key-step is described (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00344-9

文献信息

• Peptidyl calcium channel blockers
  申请人：Warner-Lambert Company

  公开号：US06423689B1

  公开（公告）日：2002-07-23

  The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.

  本发明提供了阻断钙通道的化合物，其具有下面所示的I式。本发明还提供了利用I式化合物治疗中风、脑缺血、头部创伤或癫痫的方法，以及含有I式化合物的药物组合物。
• Design of Plasma Kallikrein Inhibitors: Functional and Structural Requirements of Plasma Kallikrein Inhibitors.
  作者：Yuko TSUDA、Keiko WANAKA、Mayako TADA、Shosuke OKAMOTO、Akiko HIJIKATA-OKUNOMIYA、Yoshio OKADA

  DOI：10.1248/cpb.46.452

  日期：——

  The synthetic plasma kallikrein (PK) inhibitor trans-4-aminomethylcyclohexanecarbonylphenylalanine-4-carboxymethylanilide (PKSI-527) consists of three parts. Each part was replaced by analogues in an attempt to improve the potency and the selectivity of PKSI-527. Among the peptides examined, trans-4-aminomethylcyclohexanecarbonylphenylalanine-4-carboxyanilide (peptide 16) inhibited PK with a high selectivity and an IC50 value of 2.7μM, being as potent as PKSI-527.

  合成血浆激肽释放酶（PK）抑制剂反式-4-氨基甲基环己烷羰基苯丙氨酸-4-羧甲基苯甲酰胺（PKSI-527）由三个部分组成。尝试用类似物替换每个部分，以提高PKSI-527的效力和选择性。在检测的肽中，反式-4-氨基甲基环己烷羰基苯丙氨酸-4-羧基苯甲酰胺（肽16）对PK具有高度选择性，IC50值为2.7μM，与PKSI-527效力相当。
• Synthesis and Biological Activity of a Novel Class of Small Molecular Weight Peptidomimetic Competitive Inhibitors of Protein Tyrosine Phosphatase 1B
  作者：Scott D. Larsen、Tjeerd Barf、Charlotta Liljebris、Paul D. May、Derek Ogg、Theresa J. O'Sullivan、Barbara J. Palazuk、Heinrich J. Schostarez、F. Craig Stevens、John E. Bleasdale

  DOI：10.1021/jm010393s

  日期：2002.1.1

  sulfate with other potential phosphate mimics. The most potent analogue arising from this effort was triacid 71, which inhibits PTP1B competitively with a K(i) = 0.22 microM without inhibiting SHP-2 or LAR at concentrations up to 100 microM. Overall, the inhibitors generated in this work showed little or no enhancement of insulin signaling in cellular assays. However, potential prodrug triester 70 did induce

  蛋白质酪氨酸磷酸酶1B（PTP1B）部分地通过使胰岛素受体（IR）的β亚基调节域内的关键酪氨酸残基去磷酸化，从而负调节胰岛素信号传导，从而减弱受体酪氨酸激酶的活性。因此，抑制PTP1B有望改善胰岛素抵抗，并且最近已成为旨在鉴定用于治疗II型糖尿病的新药物的发现工作的重点。我们以前曾报道三肽Ac-Asp-Tyr（SO（3）H）-Nle-NH（2）是PTP1B的令人惊讶的有效抑制剂（K（i）= 5 microM）。为了改善该引线的稳定性和效力以及减弱其肽特性，进行了模拟程序。该程序初始阶段的具体内容包括用非氨基酸成分替换N和C末端，修饰酪氨酸亚基以及用其他潜在的磷酸盐模拟物替换硫酸酪氨酸。从这种努力中产生的最有效的类似物是三酸71，它以K（i）= 0.22 microM竞争性抑制PTP1B，而在浓度高达100 microM的情况下却不抑制SHP-2或LAR。总体而言，这项工作中产生的抑制剂在细
• Inhibitors of protein tyrosine phosphatase
  申请人：Pharmacia & Upjohn Company

  公开号：US06353023B1

  公开（公告）日：2002-03-05

  The present invention comprises small molecular weight, non-peptidic inhibitors of formula I and II of Protein Tyrosine Phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of Non-Insulin Dependent Diabetes Mellitus (NIDDM).

  本发明涉及小分子量、非肽类的蛋白酪氨酸磷酸酶1（PTP1）的化学式I和II的抑制剂，用于治疗和/或预防非胰岛素依赖型糖尿病（NIDDM）。
• Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
  申请人：——

  公开号：US20020035137A1

  公开（公告）日：2002-03-21

  Compounds of formula (I) 1 or therapeutically acceptable salts thereof, are protein tyrosine kinase PTP 1 B inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  式（I）的化合物或其治疗上可接受的盐是蛋白酪氨酸激酶PTP1B的抑制剂。公开了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。